1010 GMT - AstraZeneca is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after the company reported that Chinese authorities approved its Xigduo XR treatment for adults with type-2 diabetes. The company said that the drug combines two anti-hyperglycaemic agents with complementary mechanisms of action, and that it is the only fixed-dose combination of this kind to be approved in China. Xigduo XR is already approved in the U.S. and Australia among others, according to AstraZeneca. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)

(END) Dow Jones Newswires

June 27, 2023 06:36 ET (10:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.